KOMBINATIONSKREBSTHERAPIE

European patent · EP3675891 · In force

Register entry

Publication number
EP3675891
Application number
EP18851102
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Aug 29, 2018
Published
Jul 8, 2020
Granted
Jul 17, 2024
Protection ends at the latest
Aug 28, 2038
Next annual fee due
Aug 31, 2027
IPC classes
A61K 38/17 (2006.01)
A61K 39/395 (2006.01)
A61P 35/00 (2006.01)
C12N 15/63 (2006.01)
Priority
US 201762553363 P 01.09.2017
US 201762562636 P 25.09.2017
US 201762595106 P 06.12.2017
US 201815882181 29.01.2018
PCT application
PCT/US2018/048462 29.08.2018
PCT publication
WO2019/046377 07.03.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 24, 2026

    Next annual fee due on

    Next annual fee due on
    31.08.2026 → 31.08.2027

    Published in Swissreg on 24.09.2026

  2. Sep 25, 2025

    Next annual fee due on

    Next annual fee due on
    31.08.2025 → 31.08.2026

    Published in Swissreg on 25.09.2025

  3. May 28, 2025

    Change

    Published in Swissreg on 28.05.2025

  4. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  5. Jul 19, 2024

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 19.07.2024

  6. Jul 17, 2024

    Granted

    Published in Swissreg on 17.07.2024

Parties

Holder

MicroVAX, LLC

Mason Enterprise Center 70 Main Street Suite 23, Warrenton, VA 20186, US

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

DEISSEROTH, Albert B.

Potomac Maryland 20854, US

HABIB, Nagy

Ealing London W5 1TA, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.